FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (Chromocell, or the Company), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (œChromocell, or the œCompany), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (Chromocell, or the Company), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (Chromocell, or the Company), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (œBenuvia), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (œChromocell), (NYSE American: CHRO),...
FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (Chromocell, our, us or the Company), a clinical-stage biotech company focused on...
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Public Offering